안데르센-타윌 증후군 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 유통 채널별, 지역별, 경쟁 시장별(2020-2030년)
Andersen-Tawil Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Distribution Channel, By Region and Competition, 2020-2030F
상품코드:1703464
리서치사:TechSci Research
발행일:2025년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
안데르센-타윌 증후군(ATS) 세계 시장 규모는 2024년 226만 달러에서 2030년에는 349만 달러에 달할 것으로 예상되며, 예측 기간 동안 7.47%의 복합 연간 성장률(CAGR)을 보일 것으로 예측됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
226만 달러
시장 규모 : 2030년
349만 달러
CAGR : 2025-2030년
7.47%
급성장 부문
온라인 약국
최대 시장
북미
희귀 유전성 질환에 대한 인식 증가와 진단 기술의 발전으로 ATS 시장에 대한 관심이 높아지고 있습니다. 안데르센-타윌 증후군은 골격근, 심장 기능, 신체 발달에 영향을 미치고 종종 주기적 마비나 생명을 위협하는 부정맥을 유발하는 희귀 유전성 채널 이상 질환입니다. 의료 전문가들 사이에서 인지도가 높아지고 유전자 검사법이 개선됨에 따라 적시에 효과적인 질병 관리를 위해 필수적인 조기 진단이 가능해졌습니다.
정밀의료와 개인 맞춤형 치료 전략의 출현은 ATS 표적 치료법 개발에 더 많은 영향을 미치고 있습니다. 현재 치료 옵션은 여전히 제한적이지만, 현재 진행 중인 칼륨 채널 조절제 및 유전자 치료 연구는 큰 잠재력을 가지고 있으며, ATS 환자의 미충족 수요를 충족시키기 위한 제약사 및 연구기관의 투자 증가도 시장 성장에 기여하고 있습니다.
주요 시장 성장 촉진요인
유전자 진단의 발전
주요 시장 이슈
복잡한 증상으로 인한 진단 지연
이러한 지연은 심각한 결과를 예방하기 위해 적시에 개입하는 것이 필수적인 심장 합병증을 동반한 경우 특히 해롭습니다.
주요 시장 동향
최첨단 유전자 진단과 맞춤의료
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
질병 유형별(유형 1, 유형 2)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
질환 유형별
유통 채널별
지역별
제5장 아시아태평양의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
질환 유형별
유통 채널별
국가별
아시아태평양 : 국가별 분석
중국
인도
호주
일본
한국
제6장 유럽의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
스페인
이탈리아
영국
제7장 북미의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제8장 남미의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제9장 중동 및 아프리카의 안데르센-타윌 증후군 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제10장 시장 역학
성장 촉진요인
과제
제11장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제12장 세계의 안데르센-타윌 증후군 시장 : SWOT 분석
제13장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Merck KGA.
Grevis Pharmaceuticals
Xeris Pharma
Novartis AG
Advanz Pharmaceuticals
Alembic Pharmaceuticals
Avet Pharmaceuticals
Hikma Pharmaceuticals
Micro Labs
Advagen Pharma
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Andersen-Tawil Syndrome (ATS) market was valued at USD 2.26 million in 2024 and is projected to reach USD 3.49 million by 2030, growing at a compound annual growth rate (CAGR) of 7.47% during the forecast period.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 2.26 Million
Market Size 2030
USD 3.49 Million
CAGR 2025-2030
7.47%
Fastest Growing Segment
Online Pharmacies
Largest Market
North America
Rising awareness of rare genetic disorders, coupled with advancements in diagnostic technologies, is propelling interest in the ATS market. Andersen-Tawil Syndrome is a rare genetic channelopathy that impacts skeletal muscles, cardiac function, and physical development, often resulting in periodic paralysis and life-threatening arrhythmias. Increased recognition among healthcare professionals and improvements in genetic testing methodologies are enabling earlier diagnosis, which is critical for timely and effective disease management.
The emergence of precision medicine and personalized therapeutic strategies is further influencing the development of targeted treatments for ATS. Although current treatment options remain limited, ongoing research into potassium channel modulators and gene therapies holds significant promise. Increased investment from pharmaceutical companies and research institutions focused on addressing the unmet needs of ATS patients is also contributing to market growth.
Key Market Drivers
Advancements in Genetic Diagnostics
The growth of the ATS market is strongly supported by progress in genetic diagnostics and electrophysiology, which have significantly enhanced the identification and understanding of this rare autosomal dominant condition. ATS is primarily caused by mutations affecting potassium ion channels, leading to characteristic symptoms including cardiac arrhythmias, muscle weakness, and distinct physical traits. With an estimated prevalence of 0.08 to 0.1 per 100,000 individuals, accurate diagnosis is essential.
Improvements in next-generation sequencing (NGS) and genetic screening techniques have enabled earlier and more precise detection, resulting in better disease management. Reports indicate that approximately 76% of physicians are utilizing genetic testing for rare diseases, reflecting a growing emphasis on early identification.
The integration of artificial intelligence (AI) into diagnostic workflows is accelerating the identification of rare mutations associated with ATS, facilitating tailored treatment strategies. Furthermore, the development of rare disease registries and patient databases is enriching the collective understanding of disease progression and treatment efficacy. Regulatory support for orphan drug development and accelerated approval pathways is also fostering innovation in therapy development for ATS.
Key Market Challenges
Diagnostic Delays Due to Complex Symptomatology
A primary challenge in the ATS market lies in diagnostic delays, driven by the condition's varied and often ambiguous symptom presentation. Patients may exhibit a broad range of clinical manifestations, including cardiac arrhythmias, episodes of muscle paralysis, and unique facial features-symptoms that, while indicative of ATS, are not exclusive to it.
This clinical variability frequently leads to misdiagnoses, as symptoms may be mistaken for more common cardiac or neuromuscular conditions. Consequently, patients often receive inappropriate treatments that fail to address the underlying genetic cause.
Furthermore, limited awareness of ATS among both the general public and healthcare professionals exacerbates diagnostic delays. Due to the rarity of the condition, physicians may not consider ATS early in the diagnostic process, resulting in prolonged patient journeys involving multiple specialists and extensive testing before a definitive diagnosis is reached.
These delays can be particularly detrimental in cases involving cardiac complications, where timely intervention is essential to prevent severe outcomes.
Key Market Trends
Cutting-Edge Genetic Diagnostics and Personalized Care
Technological advancements in genetic diagnostics-particularly next-generation sequencing (NGS) and whole exome sequencing (WES)-are revolutionizing the diagnosis and management of ATS. These techniques enable the rapid and accurate identification of pathogenic mutations, including those in the KCNJ2 and CACNA1S genes, which are commonly associated with ATS.
As a result, clinicians can now deliver faster, more accurate diagnoses, facilitating timely intervention and access to appropriate treatments. These developments have also deepened scientific understanding of ATS at the molecular level, allowing researchers to explore genotype-phenotype relationships and identify novel therapeutic targets.
This expanding knowledge base is supporting the development of more effective, genetically informed treatments and is accelerating progress toward personalized medicine approaches in the ATS space. Moreover, genetic diagnostics are increasingly being used for carrier screening among family members, enabling early detection, proactive monitoring, and preventative care-further driving demand for ATS-related medical services and diagnostics.
Key Market Players
Merck KGA.
Grevis Pharmaceuticals
Xeris Pharma
Novartis AG
Advanz Pharmaceuticals
Alembic Pharmaceuticals
Avet Pharmaceuticals
Hikma Pharmaceuticals
Micro Labs
Advagen Pharma
Report Scope:
In this report, the Global Andersen-Tawil Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Andersen-Tawil Syndrome Market, By Disease Type:
Type 1
Type 2
Andersen-Tawil Syndrome Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Andersen-Tawil Syndrome Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Andersen-Tawil Syndrome Market.
Available Customizations:
Global Andersen-Tawil Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Andersen-Tawil Syndrome Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Disease Type (Type 1, Type 2)
4.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
4.2.3. By Region
4.2.4. By Company (2024)
4.3. Market Map
4.3.1. By Disease Type
4.3.2. By Distribution Channel
4.3.3. By Region
5. Asia Pacific Andersen-Tawil Syndrome Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Disease Type
5.2.2. By Distribution Channel
5.2.3. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Andersen-Tawil Syndrome Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Disease Type
5.3.1.2.2. By Distribution Channel
5.3.2. India Andersen-Tawil Syndrome Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Disease Type
5.3.2.2.2. By Distribution Channel
5.3.3. Australia Andersen-Tawil Syndrome Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Disease Type
5.3.3.2.2. By Distribution Channel
5.3.4. Japan Andersen-Tawil Syndrome Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Disease Type
5.3.4.2.2. By Distribution Channel
5.3.5. South Korea Andersen-Tawil Syndrome Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Disease Type
5.3.5.2.2. By Distribution Channel
6. Europe Andersen-Tawil Syndrome Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Disease Type
6.2.2. By Distribution Channel
6.2.3. By Country
6.3. Europe: Country Analysis
6.3.1. France Andersen-Tawil Syndrome Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Disease Type
6.3.1.2.2. By Distribution Channel
6.3.2. Germany Andersen-Tawil Syndrome Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Disease Type
6.3.2.2.2. By Distribution Channel
6.3.3. Spain Andersen-Tawil Syndrome Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Disease Type
6.3.3.2.2. By Distribution Channel
6.3.4. Italy Andersen-Tawil Syndrome Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Disease Type
6.3.4.2.2. By Distribution Channel
6.3.5. United Kingdom Andersen-Tawil Syndrome Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Disease Type
6.3.5.2.2. By Distribution Channel
7. North America Andersen-Tawil Syndrome Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Disease Type
7.2.2. By Distribution Channel
7.2.3. By Country
7.3. North America: Country Analysis
7.3.1. United States Andersen-Tawil Syndrome Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Disease Type
7.3.1.2.2. By Distribution Channel
7.3.2. Mexico Andersen-Tawil Syndrome Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Disease Type
7.3.2.2.2. By Distribution Channel
7.3.3. Canada Andersen-Tawil Syndrome Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Disease Type
7.3.3.2.2. By Distribution Channel
8. South America Andersen-Tawil Syndrome Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Disease Type
8.2.2. By Distribution Channel
8.2.3. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Andersen-Tawil Syndrome Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Disease Type
8.3.1.2.2. By Distribution Channel
8.3.2. Argentina Andersen-Tawil Syndrome Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Disease Type
8.3.2.2.2. By Distribution Channel
8.3.3. Colombia Andersen-Tawil Syndrome Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Disease Type
8.3.3.2.2. By Distribution Channel
9. Middle East and Africa Andersen-Tawil Syndrome Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Disease Type
9.2.2. By Distribution Channel
9.2.3. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Andersen-Tawil Syndrome Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Disease Type
9.3.1.2.2. By Distribution Channel
9.3.2. Saudi Arabia Andersen-Tawil Syndrome Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Disease Type
9.3.2.2.2. By Distribution Channel
9.3.3. UAE Andersen-Tawil Syndrome Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Disease Type
9.3.3.2.2. By Distribution Channel
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Andersen-Tawil Syndrome Market: SWOT Analysis
